• Dual CDK4/6 and BET Inhibition Suppresses EMT in Pancreatic

  2026-06-29

  Gu et al. demonstrate that co-inhibiting CDK4/6 and BET proteins produces a synergistic suppression of pancreatic ductal adenocarcinoma growth and epithelial-mesenchymal transition (EMT) by modulating GSK3β-mediated Wnt/β-catenin signaling. These findings highlight the complexity of pathway crosstalk in PDAC and inform future research on targeted anti-metastatic strategies.

• Dynasore (A1605): Practical Guide for Dynamin GTPase Inhibit

  2026-06-28

  Dynasore is a non-competitive dynamin GTPase inhibitor used to reversibly block endocytosis and vesicle trafficking in cell-based assays. It is best suited for dissecting dynamin-dependent pathways in cellular and neuronal systems, but is not recommended where water-based solubilization or long-term solution storage is required.

• Universal HPLC Method for Dual-Loaded Liposome Encapsulation

  2026-06-27

  This study introduces a nanoparticle exclusion HPLC method capable of accurately measuring encapsulation efficiency for both hydrophilic and lipophilic drugs in dual-loaded liposomes. The method overcomes limitations of prior techniques, offering broad applicability in nanomedicine and combination cancer therapy research.

• WM-8014: Precision KAT6A Inhibitor for Cancer Biology Resear

  2026-06-26

  WM-8014, a highly selective KAT6A inhibitor from APExBIO, enables robust and reproducible workflows for dissecting epigenetic dependencies, cell cycle arrest, and oncogene-induced senescence. Its reversible, substrate-competitive mechanism and low-nanomolar potency offer distinct advantages for translational cancer biology and advanced assay development.

• Resazurin Sodium Salt: Next-Gen iPSC Assays for Drug Discove

  2026-06-26

  Explore how Resazurin sodium salt, a premier fluorogenic oxidation-reduction indicator, is transforming iPSC-based translational research. This article provides mechanistic insight, protocol guidance, and strategic context for leveraging this dye in high-throughput disease modeling and precision drug screening, with a focus on cystic fibrosis and rare variant therapeutics.

• BAPTA-AM: Precision Cell-Permeable Calcium Chelator for Adva

  2026-06-25

  BAPTA-AM empowers researchers with unparalleled control of intracellular calcium, enabling sensitive dissection of calcium signaling, apoptosis, and neuroprotection. Leverage APExBIO's trusted cell-permeable calcium chelator for high-fidelity imaging, functional genomics, and complex mechanistic studies where reliability and reproducibility are paramount.

• Sulfachloropyridazine Modulates Cecal Microbiota in E. tenel

  2026-06-25

  The referenced study integrates 16S rRNA sequencing and metabolomics to elucidate how sulfachlorpyridazine, ethanamizuril, and their combination reshape the cecal microbiome and metabolite landscape in chickens infected with Eimeria tenella. These findings establish a link between drug intervention, pathogenic bacteria modulation, and metabolic profiles, offering new avenues for monitoring anticoccidial therapy efficacy in poultry research.

• EdU Imaging Kits (Cy5): Precision Tools for Translational Pr

  2026-06-24

  This thought-leadership article explores the evolving landscape of cell proliferation measurement, focusing on EdU Imaging Kits (Cy5) as next-generation tools for mechanistic and translational research. Drawing on recent advances in ovarian biology and miRNA regulation, it guides researchers in deploying cutting-edge S-phase DNA synthesis assays to bridge molecular discovery with applied biomedical outcomes.

• RRP Extracts Restore Hepatic Lipid Metabolism After Ischemia

  2026-06-23

  This study reveals that Radix Rehmanniae Praeparata (RRP) extracts can mitigate hepatic ischemia-reperfusion injury by rebalancing lipid metabolic pathways in hepatocytes. Mechanistic insights include AMPK activation, SREBP2 inhibition, and enhanced LXRα-mediated cholesterol efflux, providing new strategies for managing postoperative liver injury and modeling lipid metabolism disorders.

• Sulfachloropyridazine Modulates Gut Microbiota in E. tenella

  2026-06-23

  This study investigates how sulfachlorpyridazine, ethanamizuril, and their combination influence the cecal microbial and metabolite profiles in chickens infected with Eimeria tenella. By integrating 16S rRNA sequencing and metabolomics, the research reveals drug-induced shifts in bacterial taxa and metabolites, informing the design of more targeted anticoccidial and microbiome-modulating interventions.

• hiPSC-Derived Intestinal Organoids for Pharmacokinetic Model

  2026-06-22

  This study introduces a streamlined protocol for generating intestinal organoids from human pluripotent stem cells, enabling more human-relevant in vitro pharmacokinetic studies. The approach addresses major limitations of traditional models and supports advanced drug absorption and metabolism research.

• Acetylation-Regulated Spliceosome Alters PARP Inhibitor Sens

  2026-06-22

  This study reveals how acetylation of the spliceosome core protein SmD2 modulates DNA damage repair and alternative splicing in hepatocellular carcinoma (HCC). The findings demonstrate that targeting SmD2 acetylation can sensitize BRCA-proficient HCC cells to PARP inhibitors, paving the way for novel combinatorial therapeutic strategies.

• Sulfachloropyridazine Alters Cecal Microbiota in E. tenella

  2026-06-21

  This study uses high-resolution microbiome and metabolomics profiling to reveal how sulfachloropyridazine, alone and in combination with ethanamizuril, modulates the cecal microbial community and metabolite landscape in chickens infected with Eimeria tenella. The findings clarify drug-specific effects on both pathogenic and commensal bacteria, providing a system-level framework for monitoring drug efficacy and advancing poultry coccidiosis research.

• Carvedilol: Rethinking β-Adrenergic Antagonism in Translatio

  2026-06-20

  This thought-leadership piece presents a comprehensive, mechanism-driven discussion of Carvedilol’s dual β- and α1-adrenergic receptor antagonism, examining its impact on cardiovascular, vascular, and hematopoietic experimental paradigms. It integrates recent cross-species findings on hematopoietic regeneration post-transplant, highlights protocol-critical parameters, and offers strategic guidance for translational researchers aiming to harness—or avoid—Carvedilol’s multifaceted bioactivity. This article builds on established product intelligence and recent literature, linking to APExBIO’s Carvedilol offering and situating the discussion within the evolving competitive and translational research landscape.

• Coumestrol Induces Ferroptosis in RA-FLS by Stabilizing PMAI

  2026-06-19

  This study uncovers that the phytoestrogen Coumestrol can induce ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes by stabilizing mitochondrial PMAIP1 via inhibition of TRIM3-mediated degradation. These findings reveal a novel mechanism for targeting synoviocyte proliferation and inflammation, opening new avenues for selective estrogen receptor modulator research in autoimmune disease contexts.

449 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page